Mesenchymal stem cell

Medeze Commended by Frost & Sullivan for Dominating the Stem Cell Banking Market with Its Pioneering, Full Spectrum Services

Retrieved on: 
Friday, March 12, 2021

SINGAPORE, March 12, 2021 /PRNewswire/ --Based on its recent analysis of the Southeast Asia stem cell banking market, Frost & Sullivan recognizes Medeze Group with the 2020 Southeast Asia Stem Cell Banking Technology Innovation Leadership Award and the 2020 Thai Stem Cell Banking Company of the Year Award.

Key Points: 
  • SINGAPORE, March 12, 2021 /PRNewswire/ --Based on its recent analysis of the Southeast Asia stem cell banking market, Frost & Sullivan recognizes Medeze Group with the 2020 Southeast Asia Stem Cell Banking Technology Innovation Leadership Award and the 2020 Thai Stem Cell Banking Company of the Year Award.
  • Medeze has launched numerous first-to-market solutions in the Southeast Asian market and has maintained its leadership position in the Thai market with more than a 60% market share.
  • "Medeze was the first stem cell banking company in Thailand to bank mesenchymal stem cells (MSC) derived from placenta, cord tissue, and adipose tissue.
  • On top of being Thailand's largest and most experienced MSC bank, Medeze offers cord blood banking, cord tissue banking, and adipose tissue banking.

Longeveron’s Lomecel-B™ Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome (HLHS)

Retrieved on: 
Thursday, March 11, 2021

Lomecel-B is an allogeneic, bone marrow-derived medicinal signaling cell (MSC) product manufactured under cGMP in Longeverons cell processing facility in Miami, Florida.

Key Points: 
  • Lomecel-B is an allogeneic, bone marrow-derived medicinal signaling cell (MSC) product manufactured under cGMP in Longeverons cell processing facility in Miami, Florida.
  • The Lurie Childrens Hospital Internal Review Board (IRB) also reviewed and approved the protocol.
  • Dr. Kaushal was the first surgeon in the United States to administer allogeneic MSCs to a baby with HLHS.
  • Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimers disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).

Stem Cells Market Size Worth $18.4 Billion By 2028 | CAGR: 8.8%: Grand View Research, Inc.

Retrieved on: 
Tuesday, March 9, 2021

SAN FRANCISCO, March 9, 2021 /PRNewswire/ -- The global stem cells market size is expected to reach USD 18.4 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, March 9, 2021 /PRNewswire/ -- The global stem cells market size is expected to reach USD 18.4 billion by 2028, according to a new report by Grand View Research, Inc.
  • The researchers discovered a new way for creating induced trophoblast stem cells which can be used for making placenta cells.
  • The patients received a single infusion of mesenchymal stem cells (MSCs) which was found to be effective in developing an immune response.
  • Grand View Research has segmented the global stem cells market on the basis of product, application, technology, therapy, and region:
    Stem Cells Product Outlook (Revenue, USD Million, 2017 - 2028)

Stem Cells Market Size Worth $18.4 Billion By 2028 | CAGR: 8.8%: Grand View Research, Inc.

Retrieved on: 
Tuesday, March 9, 2021

SAN FRANCISCO, March 9, 2021 /PRNewswire/ -- The global stem cells market size is expected to reach USD 18.4 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, March 9, 2021 /PRNewswire/ -- The global stem cells market size is expected to reach USD 18.4 billion by 2028, according to a new report by Grand View Research, Inc.
  • The researchers discovered a new way for creating induced trophoblast stem cells which can be used for making placenta cells.
  • The patients received a single infusion of mesenchymal stem cells (MSCs) which was found to be effective in developing an immune response.
  • Grand View Research has segmented the global stem cells market on the basis of product, application, technology, therapy, and region:
    Stem Cells Product Outlook (Revenue, USD Million, 2017 - 2028)

New Preclinical Study to Investigate the High Potency of Cymerus™ MSCs

Retrieved on: 
Tuesday, March 2, 2021

Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Key Points: 
  • Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.
  • Clinical trials of Cymerus MSC products in osteoarthritis (Phase 3) and in severe complications arising from COVID-19 (Phase 2) are currently ongoing.
  • Planning is also underway for further clinical trials of Cymerus MSC products in GvHD (through licensee Fujifilm), critical limb ischemia, idiopathic pulmonary fibrosis, renal transplantation, and diabetic foot ulcers.
  • Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.

Company Profile for Hope Biosciences Stem Cell Research Foundation

Retrieved on: 
Monday, February 22, 2021

Hope Biosciences Stem Cell Research Foundation, administered through the Greater Houston Community Foundation, was founded to address the need to accelerate translational research in regenerative medicine so that therapies could be delivered to patients faster.

Key Points: 
  • Hope Biosciences Stem Cell Research Foundation, administered through the Greater Houston Community Foundation, was founded to address the need to accelerate translational research in regenerative medicine so that therapies could be delivered to patients faster.
  • The foundation is designed to not just support promising trials but to help develop innovative protocols using the latest technology to ultimately deliver high-quality data for quicker approvals.
  • Today, the foundation is leading the effort in using mesenchymal stem cells to combat COVID-19, with three FDA authorized protocols for coronavirus.
  • Current active protocols also include Cerebral Palsy, Parkinsons Disease, Spinal Cord Injury, Traumatic Brain Injury, Alzheimers Disease, ALS and Severe Osteoarthritis.

Global Mesenchymal Stem Cells (MSC) Market Report 2021-2027: Market Competitors areExploring Commercialization Strategies for MSC-Derived Extracellular Vesicles (EVs) and Exosomes

Retrieved on: 
Monday, February 15, 2021

DUBLIN, Feb. 15, 2021 /PRNewswire/ -- The "Mesenchymal Stem Cells - Advances and Applications, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 15, 2021 /PRNewswire/ -- The "Mesenchymal Stem Cells - Advances and Applications, 2021" report has been added to ResearchAndMarkets.com's offering.
  • Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes.
  • Numerous market competitors are exploring commercialization strategies for MSC-derived extracellular vesicles (EVs) and exosomes because these extracellular "packages" represent a novel strategy for accessing the therapeutic effects of stem cells without the risks of administering whole cells to patients.
  • It also presents detailed market size figures for the global MSC market, segmented by geography and business segment, accompanied by five-year forecasts through 2027.

Global Mesenchymal Stem Cells Advances and Applications Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 12, 2021

The "Mesenchymal Stem Cells - Advances and Applications, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mesenchymal Stem Cells - Advances and Applications, 2021" report has been added to ResearchAndMarkets.com's offering.
  • As the most common stem cell type being used within regenerative medicine today, there is huge potential for growth within the MSC market.
  • It also presents detailed market size figures for the global MSC market, segmented by geography and business segment, accompanied by five-year forecasts through 2027.
  • With the competitive nature of this global market, you do not have the time to do the research.

Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn’s Disease

Retrieved on: 
Wednesday, February 10, 2021

Darvadstrocel should only be administered by specialist physicians experienced in the diagnosis and treatment of conditions for which Darvadstrocel is indicated.

Key Points: 
  • Darvadstrocel should only be administered by specialist physicians experienced in the diagnosis and treatment of conditions for which Darvadstrocel is indicated.
  • Darvadstrocel is not recommended during pregnancy and in women of childbearing potential who are not using contraception.
  • Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.
  • Mahadev S, Young JM, Selby W, et al., Quality of life in perianal Crohn's disease: what do patients consider important?

BrainStorm-Cell Therapeutics to Announce Fourth Quarter and Fiscal Year 2020 Financial Results and Provide a Corporate Update

Retrieved on: 
Thursday, January 28, 2021

MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.

Key Points: 
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs).
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • The phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) completed dosing in December 2020, and topline results are expected by the end of the first quarter 2021.